David G Dibbell Jr., MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5886 |
Theresa Anne Hegge, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-5301 Fax: 701-323-5886 |
Dr. Ricky C. Becker, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5918 |
Dr. Andrew M. Mills, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 |
Dr. Steven Gary Yearsley, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th St, Bismarck, ND 58501 Phone: 701-877-2020 Fax: 701-299-4517 |
News Archive
As stroma - the supportive framework of the prostate gland - react to prostate cancer, changes in the expression of genes occur that induce the formation of new structures such as blood vessels, nerves and parts of nerves, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Clinical Cancer Research.
Waters Corporation is showcasing its portfolio of MassTrak solutions at the American Association of Clinical Chemistry annual meeting and Clinical Lab Expo July 25 - 29, 2010 in Anaheim in exhibit booth #4447. Waters portfolio of MassTrak Solutions for the clinical laboratory combines the power of separations science, tandem mass spectrometry, specialized chemistries, software, and support services in ways designed to optimize laboratory processes.
Medtronic, Inc. today announced that the company has received CE (Conformité Européenne) Mark approval for Medtronic Deep Brain Stimulation (DBS) Therapy in Europe as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. DBS therapy for epilepsy delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus, which is part of a circuit involved in seizures.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
Two new studies presented today at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, report that Mobile Stroke Treatment Units (MSTUs) can significantly reduce the time it takes to diagnose and treat patients for stroke, greatly improving survival rates and enhancing a patient's chance of recovery.
› Verified 4 days ago